{"document_type": "article", "snippet": "A research firm\u2019s report that all but called Valeant the pharmaceutical equivalent of Enron hit the stock market like a bomb Wednesday morning.", "type_of_material": "News", "web_url": "http://www.nytimes.com/2015/10/22/business/dealbook/valeants-shares-fall-on-reports-fraud-claim.html", "subsection_name": "DealBook", "blog": [], "section_name": "Business Day", "source": "The New York Times", "pub_date": "2015-10-22T00:00:00Z", "word_count": "1305", "slideshow_credits": null, "news_desk": "Business", "byline": {"person": [{"role": "reported", "lastname": "GOLDSTEIN", "rank": 1, "organization": "", "firstname": "Matthew"}, {"role": "reported", "lastname": "STEVENSON", "rank": 2, "organization": "", "firstname": "Alexandra"}, {"role": "reported", "lastname": "EAVIS", "rank": 3, "organization": "", "firstname": "Peter"}], "contributor": "Andrew Pollack contributed reporting.", "original": "By MATTHEW GOLDSTEIN, ALEXANDRA STEVENSON and PETER EAVIS"}, "abstract": "Shares of Valeant Pharmaceutical fall after report by Citron Research accuses it of accounting fraud; report contends Valeant dealt in 'phantom sales;' Pershing Square Capital head William A Ackman increases share in company.", "keywords": [{"value": "Valeant Pharmaceuticals International Inc", "rank": "1", "name": "organizations", "is_major": "Y"}, {"value": "Pershing Square Capital Management", "rank": "2", "name": "organizations", "is_major": "Y"}, {"value": "Ackman, William A", "rank": "3", "name": "persons", "is_major": "Y"}, {"value": "Drugs (Pharmaceuticals)", "rank": "4", "name": "subject", "is_major": "N"}, {"value": "Paulson & Co", "rank": "5", "name": "organizations", "is_major": "N"}, {"value": "Suits and Litigation (Civil)", "rank": "6", "name": "subject", "is_major": "N"}, {"value": "Pearson, John Michael (1959- )", "rank": "7", "name": "persons", "is_major": "N"}, {"value": "Hedge Funds", "rank": "8", "name": "subject", "is_major": "N"}, {"value": "Citron Research", "rank": "9", "name": "organizations", "is_major": "N"}], "print_page": "1", "multimedia": [{"subtype": "wide", "legacy": {"wideheight": "126", "wide": "images/2015/10/22/business/22Valeant/22Valeant-thumbWide-v2.jpg", "widewidth": "190"}, "type": "image", "width": 190, "height": 126, "url": "images/2015/10/22/business/22Valeant/22Valeant-thumbWide-v2.jpg"}, {"subtype": "xlarge", "legacy": {"xlargeheight": "399", "xlargewidth": "600", "xlarge": "images/2015/10/22/business/22Valeant/22Valeant-articleLarge.jpg"}, "type": "image", "width": 600, "height": 399, "url": "images/2015/10/22/business/22Valeant/22Valeant-articleLarge.jpg"}, {"subtype": "thumbnail", "legacy": {"thumbnail": "images/2015/10/22/business/22Valeant/22Valeant-thumbStandard-v2.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "type": "image", "width": 75, "height": 75, "url": "images/2015/10/22/business/22Valeant/22Valeant-thumbStandard-v2.jpg"}], "lead_paragraph": "A research firm\u2019s report that all but called Valeant the pharmaceutical equivalent of Enron hit the stock market like a bomb Wednesday morning.", "headline": {"print_headline": "Valeant\u2019s Shares Fall on Report\u2019s Fraud Claim", "main": "Valeant\u2019s Shares Fall on Report\u2019s Fraud Claim"}, "_id": "562840d138f0d80f1ae08bf1"}